Early Detection
Early Detection is a development-stage diagnostics company building EarlyTest, a point-of-care cancer screening test for use in doctors' offices, intended to detect cancer at all stages and future cancer risk; it is pre-revenue and pre-commercialization.
- Company typePrivate
- Founded2017
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Early Detection does
Early Detection, Inc. (EDI) is a development-stage medical diagnostics company incorporated in Nevada and operating from San Diego, California. The company is developing a single product, EarlyTest, which it describes as the world's first point-of-care cancer screening test, designed to be administered in a doctor's office and intended to detect cancer at all stages of disease as well as identify risk of future cancers. The company serves healthcare providers and medical practices as the intended distribution channel, with patients as end users. No underlying technology platform, clinical methodology, biomarker panel, or device architecture is publicly described in the source material, and no patents, peer-reviewed publications, clinical trial results, or regulatory filings are disclosed.
The intended business model is a sales-led, B2B2C distribution in which the company would generate revenue through one-time sale of diagnostic test kits to physicians and medical practices. The product has not yet been commercialized, and the company is pre-revenue. The company is privately held with no disclosed funding rounds, institutional investors, headcount, management team, executive leadership, partnerships, awards, or third-party endorsements on record. Its public presence is limited to a Squarespace-hosted website at cancer.us, a LinkedIn company page, a registered office in Carson City, Nevada, and a mailing address in Coronado, California. The terms of use restrict the intended audience to US residents, indicating a US-only commercial focus at this stage. The aggregate evidence base supporting Early Detection's clinical and commercial viability is thin and consists almost entirely of first-party, self-published marketing claims.
Early Detection firmographics
Firmographics- Name
- Early Detection
- Legal name
- Early Detection, Inc.
- Website
- https://cancer.us
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Early Detection is a development-stage diagnostics company building EarlyTest, a point-of-care cancer screening test for use in doctors' offices, intended to detect cancer at all stages and future cancer risk; it is pre-revenue and pre-commercialization.
- Ownership category
- akta.pro rank
Early Detection industry classification
Industry- Product category
- Cancer Diagnostic Devices
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industry
- Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)
Keywords
Where Early Detection is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Early Detection business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- EarlyTest diagnostic test: The company is developing a medical diagnostic product (EarlyTest) for cancer screening. As a point-of-care diagnostic test, revenue would likely be generated through sale of test kits to healthcare providers and medical practices. The product is still in development phase.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Early Detection product offering
Product offeringCore offering
Early Detection is developing EarlyTest, a point-of-care cancer screening test administered directly in a doctor's office. The product is designed to detect cancer at all stages of disease progression and identify the risk of future cancers before they develop. The test is intended to be sold to healthcare providers and medical practices as a screening tool used in routine patient care.
Product overview
Early Detection is developing a single unified product called EarlyTest, described as the world's first point-of-care cancer screening test. The product is designed to be administered directly in a doctor's office, enabling patients to detect cancer at all stages and identify risk of future cancers.
Differentiator
Problem solved
Functional benefit
Products and services
- EarlyTest A point-of-care cancer screening test designed to detect cancer at all stages of disease progression and assess the risk of future cancers, administered directly in a doctor's office setting and intended for use by healthcare providers and their patients.
Companies that use Early Detection
Customer profileSegments1 record
Ideal customer profiles1 record
Early Detection technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Early Detection partnerships and signals
Strategic signalScale indicators2 records
Recent moves3 records
Expansion highlights3 records
Early Detection competitors and assessment
Company assessmentDirect peers
- GRAIL: GRAIL develops the Galleri multi-cancer early detection test. It is the most direct competitor to Early Detection's EarlyTest, as both target multi-cancer screening in a blood-based format, though GRAIL currently ships to a lab rather than at point of care.
- Exact Sciences: Exact Sciences markets Cologuard, the leading non-invasive colorectal cancer screening test, and acquired Thrive Earlier Detection. It is a direct peer in non-invasive cancer screening diagnostics targeting primary-care prescribing.
- Guardant Health: Guardant Health offers liquid biopsy-based oncology tests including Guardant360 and the Shield colorectal cancer screening test. It directly competes with Early Detection in blood-based cancer detection and screening.
- Freenome: Freenome is developing a multi-cancer early detection test using a blood-based multimodal approach. It is an emerging direct peer pursuing similar early-detection screening goals to EarlyTest.
- Natera: Natera's Signatera is a leading tumor-informed minimal residual disease (MRD) and recurrence monitoring test. It is comparable as an oncology blood-based diagnostic developer pursuing screening-adjacent use cases.
Emerging players
- Thrive Earlier Detection: Thrive developed a blood-based multi-cancer screening test (CancerSEEK) and was acquired by Exact Sciences. It is a comparable emerging player in multi-cancer early detection.
Broad incumbents
- Hologic: Hologic is a large diagnostics and medical device company with a women's health and molecular diagnostics franchise (e.g., ThinPrep, Panther platform). It represents a broad incumbent with overlapping diagnostic capabilities.
- Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory networks in the US, offering a broad menu of cancer diagnostics. It is a broad incumbent whose screening franchise could compete with or distribute for point-of-care cancer tests.
- Laboratory Corporation of America (Labcorp): Labcorp is a major US clinical laboratory offering cancer screening and diagnostic services. It is a broad incumbent comparable on the diagnostics delivery model rather than product technology.
- Bio-Techne: Bio-Techne is a life sciences tools and diagnostics company with a portfolio of cancer-related reagents and assay platforms (e.g., ExoDx). It is a broad incumbent in cancer diagnostics with comparable technology overlaps.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights4 records
Customer concentration
Early Detection social profiles
Digital presenceEarly Detection financial estimates
Financial estimateRevenue estimate
Valuation estimate
Early Detection leadership team
Management profileNumber of profiles
Early Detection funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Early Detection M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Early Detection
What does Early Detection do?
Early Detection is developing EarlyTest, a point-of-care cancer screening test administered directly in a doctor's office. The product is designed to detect cancer at all stages of disease progression and identify the risk of future cancers before they develop. The test is intended to be sold to healthcare providers and medical practices as a screening tool used in routine patient care.
Is Early Detection a public or private company?
Early Detection is a private company. It is classified as unknown and is currently operating.
When was Early Detection founded?
Early Detection was founded in 2017. It employs 1 to 10 people.
Where is Early Detection based?
Early Detection is headquartered in San Diego, United States, in the North America region.
How does Early Detection make money?
One revenue line is on record: earlyTest diagnostic test.
Who are Early Detection's main competitors?
Direct peers on record are GRAIL, Exact Sciences, Guardant Health, Freenome and Natera. Thrive Earlier Detection is listed as an emerging player. Broad incumbents are Hologic, Quest Diagnostics, Laboratory Corporation of America (Labcorp) and Bio-Techne.
Does Early Detection have an API?
No public API is recorded for Early Detection.
What industry is Early Detection in?
Early Detection's product category is Cancer Diagnostic Devices. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics. Its NAICS code is 325413 and its SIC code is 2835.